INMD

NASDAQ Healthcare

InMode Ltd. - Ordinary Shares

Medical Devices

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

๐Ÿ“Š Market Data
Price$14.41
Volume305,594
Market Cap913.00M
Beta2.120
RSI (14-Day)60.5
200-Day MA$14.47
50-Day MA$13.85
52-Week High$16.74
52-Week Low$12.72
P/E Ratio10.08
Forward P/E9.41
Price / Book1.34
๐ŸŽฏ Investment Strategy Scores

INMD scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 92/100โ–ฒ +2
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 48/100โ–ฒ +11
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 62/100โ–ผ -17
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (92/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (5/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find INMD in your text

Paste any article, transcript, or post โ€” the tool will extract INMD and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.